Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease
Danna Jennings, Sarah Huntwork‐Rodriguez, Maurits F. J. M. Vissers, et al.
Movement Disorders (2023) Vol. 38, Iss. 3, pp. 386-398
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Pathogenesis of Parkinson’s Disease
Bin Xiao, Zhidong Zhou, Yinxia Chao, et al.
Neurologic Clinics (2025)
Closed Access | Times Cited: 2
Autophagy in Parkinson’s Disease
Lior Nechushtai, Dan Frenkel, Ronit Pinkas‐Kramarski
Biomolecules (2023) Vol. 13, Iss. 10, pp. 1435-1435
Open Access | Times Cited: 34
Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM
Hanwen Zhu, Patricia Hixson, Wen Ma, et al.
Cell Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 15
A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells
Yahaira Naaldijk, Belén Fernández, Rachel Fasiczka, et al.
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 11
Updated MDSGene review on the clinical and genetic spectrum of LRRK2 variants in Parkinson´s disease
Cleusa Adriane Menegassi Bianchi Krüger, Shen‐Yang Lim, Alissa Buhrmann, et al.
npj Parkinson s Disease (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 1
How should we be using biomarkers in trials of disease modification in Parkinson’s disease?
Nirosen Vijiaratnam, Thomas Foltynie
Brain (2023) Vol. 146, Iss. 12, pp. 4845-4869
Open Access | Times Cited: 21
LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting
Yulan Xiong, Jianzhong Yu
Trends in Molecular Medicine (2024) Vol. 30, Iss. 10, pp. 982-996
Closed Access | Times Cited: 7
Parkinson’s disease therapy: what lies ahead?
Andreas Wolff, Nicolas U Schumacher, Dominik Pürner, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 6, pp. 793-820
Open Access | Times Cited: 15
Natural Products as the Potential to Improve Alzheimer’s and Parkinson’s Disease
Sung Wook Kim, Jun Ho Lee, Bumjung Kim, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8827-8827
Open Access | Times Cited: 14
Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson’s disease
Makoto Naoi, Wakako Maruyama, Masayo Shamoto‐Nagai, et al.
Journal of Neural Transmission (2024) Vol. 131, Iss. 6, pp. 639-661
Closed Access | Times Cited: 5
Pharmacotherapy for Disease Modification in Early Parkinson’s Disease: How Early Should We Be?
Philipp Mahlknecht, Werner Poewe
Journal of Parkinson s Disease (2024) Vol. 14, Iss. s2, pp. S407-S421
Open Access | Times Cited: 4
Proposed biological definitions of Parkinson's disease confuse understanding without delivering meaningful advances
Francisco Cardoso, Péter Schmidt
Journal of Parkinson s Disease (2025)
Open Access
Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain
Enrico Bagnoli, Yu‐En Lin, Sophie Burel, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 5
Open Access
Precision Medicine in Parkinson’s Disease
Gadi Maayan Eshed, Roy N. Alcalay
Neurologic Clinics (2025) Vol. 43, Iss. 2, pp. 365-381
Closed Access
Identification of Potent Leucine‐Rich Repeat Kinase 2 Inhibitors by Virtual Screening and Biological Evaluation
Hualiang Shen, Guoqi Yu, Tao Cai, et al.
Chemical Biology & Drug Design (2025) Vol. 105, Iss. 3
Closed Access
Advances in autophagy for Parkinson’s disease pathogenesis and treatment
Xiaojie Zhang, Huan Zhang, Jie Dong, et al.
Ageing and Neurodegenerative Diseases (2025) Vol. 5, Iss. 1
Open Access
LRRK2 reduces the sensitivity to TKI and PD-1 blockade in ccRCC via activating LPCAT1
Yulong Hong, Weidong Li, Zhuo Xing, et al.
Oncogene (2025)
Closed Access
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Jeffrey L. Cummings, Charlotte E. Teunissen, Brian Fiske, et al.
Nature Reviews Drug Discovery (2025)
Closed Access
LRRK2 rare-variant per-domain genetic burden in Parkinson’s Disease: association confined to the kinase domain
Sitki Cem Parlar, Konstantin Senkevich, Eric Yu, et al.
npj Parkinson s Disease (2025) Vol. 11, Iss. 1
Open Access
Protein Translation in the Pathogenesis of Parkinson’s Disease
Daniyal Ashraf, Mohammed Repon Khan, Ted M. Dawson, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2393-2393
Open Access | Times Cited: 3
Targeted protein degradation for the treatment of Parkinson’s disease: Advances and future perspective
Roshanak Amirian, Mehdi Azadi Badrbani, Hossein Derakhshankhah, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 166, pp. 115408-115408
Open Access | Times Cited: 9
The autophagy–lysosome pathway: a potential target in the chemical and gene therapeutic strategies for Parkinson’s disease
Fengjuan Jiao, Lingyan Meng, Kang Du, et al.
Neural Regeneration Research (2024) Vol. 20, Iss. 1, pp. 139-158
Open Access | Times Cited: 2
Single molecule array measures of LRRK2 kinase activity in serum link Parkinson’s disease severity to peripheral inflammation
Yuan Yuan, Huizhong Li, Kashyap Sreeram, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Designing multitarget ligands for neurodegenerative diseases with improved permeability trough PLGA nanoencapsulation
Vanesa Nozal, Paula Fernández-Gómez, Alfonso García‐Rubia, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116626-116626
Open Access | Times Cited: 2
Single molecule array measures of LRRK2 kinase activity in serum link Parkinson’s disease severity to peripheral inflammation
Yuan Yuan, Huizhong Li, Kashyap Sreeram, et al.
Molecular Neurodegeneration (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top